Detalhe da pesquisa
1.
Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation.
Value Health
; 23(12): 1523-1533, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33248507
2.
Provider costs for prevention and treatment of cardiovascular and related conditions in low- and middle-income countries: a systematic review.
BMC Public Health
; 15: 1183, 2015 Nov 26.
Artigo
Inglês
| MEDLINE | ID: mdl-26612044
3.
Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
Pharmacoeconomics
; 37(10): 1287-1300, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31270747
4.
The Authors Respond: Reframing the Value of Treatments for Relapsed Refractory Multiple Myeloma.
J Manag Care Spec Pharm
; 24(7): 712-713, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29952702
5.
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States.
J Manag Care Spec Pharm
; 24(1): 29-38, 2018 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-29290170
6.
The consequences of tobacco tax on household health and finances in rich and poor smokers in China: an extended cost-effectiveness analysis.
Lancet Glob Health
; 3(4): e206-16, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25772692